| 1 |
国家卫生健康委员会. 新型冠状病毒感染的肺炎重症、危重症病例诊疗方案(试行) [EB/OL]. 2020-01-22.
URL
|
| 2 |
杨毅，邱海波. 打赢新型冠状病毒感染肺炎疫情阻击战：重症医学必须走在前面 [J/OL]. 中华重症医学电子杂志, 2020, 06: 网络预发表.
|
| 3 |
World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance [Z]. 2020-02-12.
|
| 4 |
国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案（试行第六版） [EB/OL]. 2020-02-19.
URL
|
| 5 |
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States [J]. N England J Med, 2020.
|
| 6 |
中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版) [J]. 中华结核和呼吸杂志, 2018, 41(4): 255-280.
|
| 7 |
Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study [J]. Crit Care Med, 2007, 35(12): 2693-2701.
|
| 8 |
Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock [J]. Cochrane Database Syst Rev, 2013, (9): CD001090.
|
| 9 |
Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial [J]. Crit Care, 2013, 17(1): R8.
|
| 10 |
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020, 395(10223): 507-513.
|
| 11 |
Song Y, Yao C, Yao Y, et al, XueBiJing Injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial [J]. Crit Care Med, 2019, 47(9): e735-e743.
|
| 12 |
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [J]. JAMA, 2020 Feb 7.
|
| 13 |
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020 Jan 30.
|
| 14 |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020 Jan 24.
|
| 15 |
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury [J]. Nephron Clin Pract, 2012, 120(4): c179-c184.
|
| 16 |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 [J]. Intensive Care Med, 2017, 43(3): 304-377.
|
| 17 |
中华医学会重症医学分会. 中国成人ICU镇痛和镇静治疗指南 [J/OL]. 中华重症医学电子杂志, 2018, 4(2): 90-113.
|
| 18 |
Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU [J]. Crit Care Med, 2018, 46(9): e825-e873.
|
| 19 |
WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance [Z]. 2020-01.
|
| 20 |
靳英辉，蔡林，程真顺, 等. 新型冠状病毒(2019-nCoV)感染的肺炎诊疗快速建议指南(标准版) [J]. 解放军医学杂志, 2020, 45(1): 1-20.
|
| 21 |
Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit [J]. Clin Nutr, 2019, 38(1): 48-79.
|
| 22 |
Blaser AR, Starkopf J, Alhazzani W, et al. Early enteral nutrition incritically ill patients: ESICM Clinical Practice Guidelines [J]. Intensive Care Med, 2017, 43(3): 380-398.
|
| 23 |
McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) [J]. JPEN J Parenter Enteral Nutr, 2016, 40(2): 159-211.
|
| 24 |
全国人民代表大会常务委员会. 中华人民共和国传染病防治法 [S]. 2013-06-29.
|
| 25 |
国家卫生健康委员会. 国家卫生健康委办公厅关于印发新型冠状病毒感染的肺炎防控中常见医用防护用品使用范围指引（试行）的通知 [Z]. 国卫办医函[2020]75号.
|
| 26 |
WHO. WHO Interim guidance: Clinical management of severe acute respiratory infection when novelcoronavirus (2019-nCoV) infection is suspected [Z]. 2020.
|
| 27 |
郑瑞强，胡明，李绪言, 等. 重症新型冠状病毒肺炎呼吸治疗流程专家建议 [J/OL]. 中华重症医学电子杂志, 2020, 06: 网络预发表.
|
| 28 |
Mahmoud A, Mahmoud HE, Mahran MA, et al. Streptokinase versus unfractionated heparin nebulization in patients with severe acute respiratory distress syndrome (ARDS): a randomized controlled trial with observational controls [J]. J Cardiothorac Vasc Anesth, 2020, 34(2): 436-443.
|
| 29 |
Artigas A, Camprubí-Rimblas M, Tantinyà N, et al. Inhalation therapies in acute respiratory distress syndrome [J]. Ann Transl Med, 2017, 5(14): 293.
|
| 30 |
Zhao J, Perera RAPM, Kayali G, et al. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection [J]. J Virol, 2015, 89(11): 6117-6120.
|
| 31 |
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis [J]. J Infect Dis, 2015, 211(1): 80-90.
|
| 32 |
Treatment of MERS-CoV: Information for Clinicians Clinical decision-making support for treatment of MERS-CoV patients [M]. 4th. Public Health England, 2017.
|
| 33 |
Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study [J]. Lancet Infect Dis, 2014, 14(11): 1090-1095.
|
| 34 |
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects [J]. PLoS Med, 2006, 3(9): e343.
|